{
    "organizations": [],
    "uuid": "f615d4a1a3b043a76e35dc701d45e27a9ee3e880",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fujian-cosunter-pharmaceutical-rec/brief-fujian-cosunter-pharmaceutical-receives-gmp-certificate-idUSL4N1QQ35F",
    "ord_in_thread": 0,
    "title": "BRIEF-Fujian Cosunter Pharmaceutical receives GMP certificate",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8(Reuters) - Fujian Cosunter Pharmaceutical Co Ltd :\n* Says it received goods manufacture practice (GMP) certificate from Fujian Food and Drug Administration\n* Says certificate issued to adefovir dipivoxil manufactured by the company and the valid period is until Feb. 22, 2023\nSource text in Chinese: goo.gl/J3DEyk\nFurther company coverage: (Beijing Headline News)\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-08T16:01:00.000+02:00",
    "crawled": "2018-03-09T14:46:39.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "fujian",
        "cosunter",
        "pharmaceutical",
        "co",
        "ltd",
        "say",
        "received",
        "good",
        "manufacture",
        "practice",
        "gmp",
        "certificate",
        "fujian",
        "food",
        "drug",
        "administration",
        "say",
        "certificate",
        "issued",
        "adefovir",
        "dipivoxil",
        "manufactured",
        "company",
        "valid",
        "period",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}